Trials / Active Not Recruiting
Active Not RecruitingNCT06163898
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alnuctamab | Specified dose on specified days |
| DRUG | Mezigdomide | Specified dose on specified days |
| DRUG | Dexamethasone | Specified dose on specified days |
Timeline
- Start date
- 2024-02-27
- Primary completion
- 2025-05-30
- Completion
- 2025-05-30
- First posted
- 2023-12-11
- Last updated
- 2025-04-04
Locations
6 sites across 2 countries: United States, Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06163898. Inclusion in this directory is not an endorsement.